Seroatlas · Human Serome Atlas

ADRB2

Beta-2 adrenergic receptor

Also known as: ADRB2_HUMAN, ADRB2R, ADRBR, B2AR, BAR

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P07550
Gene
ADRB2
Ensembl
ENSG00000169252
Chromosome
5
Canonical length
413 aa
Protein class
FDA approved drug targets, G-protein coupled receptors, Human disease related genes, Predicted membrane proteins, Transporters
Subcellular location
Plasma membrane,Microtubules,Cytokinetic bridge,Mitotic spindle,Primary cilium,Basal body

OverviewNCBI Gene

This gene encodes beta-2-adrenergic receptor which is a member of the G protein-coupled receptor superfamily. This receptor is directly associated with one of its ultimate effectors, the class C L-type calcium channel Ca(V)1.2. This receptor-channel complex also contains a G protein, an adenylyl cyclase, cAMP-dependent kinase, and the counterbalancing phosphatase, PP2A. The assembly of the signaling complex provides a mechanism that ensures specific and rapid signaling by this G protein-coupled receptor. This receptor is also a transcription regulator of the alpha-synuclein gene, and together, both genes are believed to be associated with risk of Parkinson's Disease. This gene is intronless. Different polymorphic forms, point mutations, and/or downregulation of this gene are associated with nocturnal asthma, obesity, type 2 diabetes and cardiovascular disease. [provided by RefSeq, Oct 2019]

Canonical amino-acid sequenceUniProt

413 residues, UniProt reviewed canonical sequence.

>P07550|ADRB2
     1  MGQPGNGSAF LLAPNGSHAP DHDVTQERDE VWVVGMGIVM SLIVLAIVFG NVLVITAIAK
    61  FERLQTVTNY FITSLACADL VMGLAVVPFG AAHILMKMWT FGNFWCEFWT SIDVLCVTAS
   121  IETLCVIAVD RYFAITSPFK YQSLLTKNKA RVIILMVWIV SGLTSFLPIQ MHWYRATHQE
   181  AINCYANETC CDFFTNQAYA IASSIVSFYV PLVIMVFVYS RVFQEAKRQL QKIDKSEGRF
   241  HVQNLSQVEQ DGRTGHGLRR SSKFCLKEHK ALKTLGIIMG TFTLCWLPFF IVNIVHVIQD
   301  NLIRKEVYIL LNWIGYVNSG FNPLIYCRSP DFRIAFQELL CLRRSSLKAY GNGYSSNGNT
   361  GEQSGYHVEQ EKENKLLCED LPGTEDFVGH QGTVPSDNID SQGRNCSTND SLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ADRB2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
7
Mean surface accessibility (rSASA)
0.39
Highest tissue expression
37 nTPM

Expression across tissuesHPA

Tissue

  • skin: 37 nTPM
  • breast: 32 nTPM
  • adipose tissue: 26 nTPM
  • lung: 18 nTPM
  • esophagus: 14 nTPM
  • liver: 13 nTPM

Single-cell type

  • basal keratinocytes: 326 nCPM
  • breast lactating cells: 231 nCPM
  • suprabasal keratinocytes: 185 nCPM
  • alveolar cells type 1: 175 nCPM
  • ocular epithelial cells: 153 nCPM
  • mast cells: 139 nCPM

Immune cell

  • gdT-cell: 152 nTPM
  • MAIT T-cell: 113 nTPM
  • memory CD8 T-cell: 93 nTPM
  • eosinophil: 68 nTPM
  • naive CD8 T-cell: 54 nTPM
  • non-classical monocyte: 54 nTPM

Brain region

  • white matter: 15 nTPM
  • thalamus: 15 nTPM
  • spinal cord: 13 nTPM
  • pons: 13 nTPM
  • medulla oblongata: 13 nTPM
  • midbrain: 12 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ADRB2.

Disease | AutoantibodyPubMed

Conditions in which antibodies against ADRB2 are reported. Each links to that disease's full target list.

    Showing 0 of 1 — disease pages carrying at least 10 antigens.

    ReferencesPubMed · IEDB

    Publications for ADRB2 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

    Reference: AutoantibodyPubMed

    19 publications

    Show 14 more

    Reference: B cellIEDB

    1 publication

    Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

    Genetic constraint and essentialitygnomAD · DepMap

    Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

    gnomAD LOEUF (loss-of-function intolerance)
    0.59
    gnomAD pLI
    0.53
    gnomAD missense Z
    1.35
    DepMap mean gene effect
    0.03
    DepMap dependency class
    selective

    Cancer expressionTCGA

    Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

    OntologyGO

    Biological processes

    Molecular functions

    Cellular components

    Protein domainsUniProt · Pfam · InterPro

    KeywordsUniProt

    InteractionsUniProt · HPA

    Protein binding partners of ADRB2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

    Antibody and autoantibody relevanceSeroatlas analysis

    Seroatlas reads ADRB2 as an antibody target. Whether an autoantibody or antibody against ADRB2 could matter depends on whether native ADRB2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

    ADRB2 is annotated at the cell surface, where native ADRB2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

    Annotation status

    The present source text does not explicitly label ADRB2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

    Canonical record: https://seroatlas.com/gene/ADRB2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

    Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

    © 2026 · Seroatlas, Discover Oregon LLC · Terms of use

    Loading the interactive Seroatlas protein explorer...